VectorBuilder pioneers cutting-edge innovation for AAV gene delivery, with a one-stop solution supporting programs from research to early discovery to clinical development. Its proprietary technology ...

UC101 is the world’s first FDA IND-approved umbilical cord blood-derived allogeneic CAR-T therapy. T cells derived from umbilical cord blood possess the natural advantages of low immunogenicity and ...

CHICAGO--(BUSINESS WIRE)--GSL Biotech and VectorBuilder have formed a partnership to create a complete cloning solution, allowing customers to order their entire custom plasmids directly from ...

GUANGZHOU, China, Nov. 26, 2024 /PRNewswire/ -- VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the ...

VectorBuilder Biotechnology has secured investor backing for its push to support gene delivery, raising a 410 million Chinese yuan ($57 million) series C financing round to upgrade and expand its R&D ...

VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable ...

Chicago-based VectorBuilder will drop $500 million over the next four years in a two-phase project to build a new gene therapy manufacturing facility and research institute in Guangzhou, China. The ...

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease NORWICH, England & CHICAGO-- ...

VectorBuilder Inc. has announced its plan to invest $30 million to build an ‘AAV Superbank’ for the research and drug discovery community. The company will develop a comprehensive collection of novel ...

VectorBuilder will expand with the construction of new $500 million Gene Delivery Research and Manufacturing Campus in Guangzhou, China. VectorBuilder, a global gene delivery solutions company, ...

VectorBuilder’s proprietary capsid technology will allow IKAR-003 to be delivered to the eye via the minimally invasive intravitreal route in a doctor’s office. This will enhance access to the ...